Literature DB >> 7882381

Complete response of metastatic renal cell carcinoma to low-dose interferon-gamma treatment.

F Otto1, A Mackensen, R Mertelsmann, R Engelhardt.   

Abstract

The course of metastatic renal cell carcinoma may be positively influenced by immunotherapeutic agents. We report a case of renal cell carcinoma showing a complete response to once-weekly low-dose s. c. interferon-gamma (IFN gamma) treatment in multiple metastatic sites (lung, chest wall, abdomen, vertebral body), but concomitantly developing a solitary brain metastasis. High initial interleukin-6 (IL-6) levels returned to normal during IFN treatment suggesting that IFN gamma may have interrupted an autocrine IL-6/IL-6-receptor loop of the tumor cells. The duration of complete remission in the extracerebral sites is now 46+ months. IFN gamma may be less active beyond the blood/brain barrier.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7882381     DOI: 10.1007/bf01520293

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  14 in total

1.  Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients.

Authors:  R Engelhardt; A Mackensen; C Galanos
Journal:  Cancer Res       Date:  1991-05-15       Impact factor: 12.701

2.  Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.

Authors:  J Y Blay; S Negrier; V Combaret; S Attali; E Goillot; Y Merrouche; A Mercatello; A Ravault; J M Tourani; J F Moskovtchenko
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

3.  Interleukin-6 and renal cell cancer: production, regulation, and growth effects.

Authors:  A S Koo; C Armstrong; B Bochner; T Shimabukuro; C L Tso; J B deKernion; A Belldegrum
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

4.  Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.

Authors:  J Gauldie; C Richards; D Harnish; P Lansdorp; H Baumann
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

5.  Biological response to intravenously administered endotoxin in patients with advanced cancer.

Authors:  R Engelhardt; A Mackensen; C Galanos; R Andreesen
Journal:  J Biol Response Mod       Date:  1990-10

6.  Relapse in the central nervous system in melanoma patients successfully treated with biomodulators.

Authors:  M S Mitchell
Journal:  J Clin Oncol       Date:  1989-11       Impact factor: 44.544

7.  Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma.

Authors:  W Aulitzky; G Gastl; W E Aulitzky; M Herold; J Kemmler; B Mull; J Frick; C Huber
Journal:  J Clin Oncol       Date:  1989-12       Impact factor: 44.544

8.  Interferon-gamma interrupts autocrine growth mediated by endogenous interleukin-6 in renal-cell carcinoma.

Authors:  H J Gruss; M A Brach; R H Mertelsmann; F Herrmann
Journal:  Int J Cancer       Date:  1991-11-11       Impact factor: 7.396

9.  Recombinant human B cell stimulatory factor 2 (BSF-2/IFN-beta 2) regulates beta-fibrinogen and albumin mRNA levels in Fao-9 cells.

Authors:  T Andus; T Geiger; T Hirano; H Northoff; U Ganter; J Bauer; T Kishimoto; P C Heinrich
Journal:  FEBS Lett       Date:  1987-08-31       Impact factor: 4.124

10.  [Results of low dosage cyclic interferon-gamma therapy of metastatic renal cell carcinoma].

Authors:  G Hofmockel; M P Wirth; D Heimbach; H G Frohmüller
Journal:  Urologe A       Date:  1993-07       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.